Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Completed · Phase 2

Conditions studied: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

In brief

The purpose of this study is to test the effectiveness, safety and tolerability of the drug combination: gemcitabine, carboplatin and bevacizumab in patients that have been diagnosed with platinum sensitive recurrent ovarian cancer, fallopian tube or primary peritoneal cancer.

Key facts

Study ID: NCT00267696
Run by: Ohio State University Comprehensive Cancer Center
People needed: 45
Starts: 2005-11-01
Expected to finish: 2013-12-01
Last updated by the study team: 2015-04-30

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Cancer of the ovaries, fallopian tube or abdominal lining has come back after more than 6 months from the last platinum based chemotherapy treatment.
Disease must be detected by CT or CA125 level must be elevated or cancerous ascites must be present.
History of at least one therapy of platinum based chemotherapy.

You may not qualify if…

Participation in another experimental drug study
Heart disease or high blood pressure
History of a stroke within the past 6 months
Vascular disease, or bleeding problems
Brain cancer
Major Surgical Procedure within 28 days prior to start date
Minor surgical procedures within 7 days prior to start date
Pregnant or lactating
Abdominal or bowel problems like bleeding
History of abdominal fistula, GI perforation or Intra-abdominal abscess
Serious, non-healing wound, ulcer or bone fracture
Acute hepatitis
Active infections requiring antibiotics
Inability to comply with study or follow up procedures

Where it is running

The Ohio State University & James Cancer Hospital — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.